![SMIS Quarterly Seminar @ Zoom:](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2020/05/smis-seminar-aug2020-300x300.jpg)
Stanford Molecular Imaging Scholars (SMIS) Program Quarterly Seminar
Zoom meeting: https://stanford.zoom.us/j/99117388314?pwd=R29OSjlTdUt0a3pLaG5Zc1BFNTJIUT09
Password: 922183
Guolan Lu, PhD
Mentor: Eben Rosenthal, MD; Garry Nolan, PhD
“Co-administered Antibody Improves the Penetration of Antibody-Dye Conjugates into Human Cancers: Implications for AntibodyDrug Conjugates”
Dianna Jeong, PhD
Mentors: Craig Levin, PhD; Shan Wang, PhD
“Novel Detection Approaches for Achieving Ultra-fast time resolution for PET”
![PHIND Seminar - Sylvia Plevritis, Ph.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/sylvia-plevritis_profilephoto-300x300.jpg)
PHIND Seminar Series: Identifying Fibroblasts Subtypes Contributing to the Progression of Preinvasive to Invasive Lung Adenocarcinoma
Sylvia Plevritis, Ph.D.
Professor of Biomedical Data Science and of Radiology
Integrative Biomedical Imaging Informatics at Stanford
Stanford University
Location
Webinar URL: https://stanford.zoom.us/s/93945120934?pwd=a29GNjFCUzBtWjRsbFdnUnVUOTMzUT09
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 939 4512 0934
Password: 767148
11:00am – 12:00pm Seminar & Discussion
RSVP: https://www.onlineregistrationcenter.com/SPlevritis
ABOUT
Dr. Sylvia K. Plevritis is Professor and Chair of Biomedical Data Science, Professor of Radiology at Stanford University and Program Director of the Stanford Biomedical Informatics Graduate Training Program. Dr. Plevritis leads a computational biology cancer research program that bridges genomics, imaging and population sciences to decipher properties of cancer progression and treatment response. Dr. Plevritis received her Ph.D. in Electrical Engineering and M.S. in Health Services Research, both from Stanford University, with a focus on cancer imaging physics and modeling cancer outcomes, respectively. She has had a primary authorship role on over 100 scientific cancer-related articles. She is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and Distinguished Investigator in the Academy of Radiology Research. She serves on the NCI Board of Scientific Advisors, the Program Leadership Committee of the Stanford Cancer Institute and the Leadership Council of the Stanford Bio-X Program. Dr. Plevritis has served on numerous NIH study sections, chaired scientific programs for the several professional societies including the American Association for Cancer Research (AACR) and presented keynote lectures across multiple scales of computational cancer biology. Currently, she is the Program Director of the Stanford Center in Cancer Systems Biology (CCSB) and has been a Principal Investigator with the NCI Cancer Intervention Surveillance Network (CISNET) for over fifteen years. She has served as Program Director of the Stanford Cancer Systems Biology Scholars Program (CSBS), and co-Division Chief of Integrative Biomedical Imaging Informatics at Stanford (IBIIS).
Sponsored by the PHIND Center and the Department of Radiology
![PHIND Seminar - Soody Tronson, M.S., J.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/SoodyT-248x300.png)
PHIND Seminar Series: Maintaining Competitive Advantage through Intellectual Capital
Soody Tronson, M.S., J.D.
Founder
Presque
Location & Timing
11:00am – 12:00pm Seminar & Discussion
Webinar URL: https://stanford.zoom.us/s/98817009379?pwd=U21pYnpCTUlxY3U2TEh4RmhvMXpvQT09
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 988 1700 9379
Password: 767148
RSVP: https://www.onlineregistrationcenter.com/STronson
ABSTRACT
Digital health has provided a range of solutions, including health and wellness-related management, machine learning algorithms for pattern recognition, AI for genetic analysis, AI-enhanced clinical decision making, and virtual doctors that use AI for patient intake triage. Intellectual property can play an important role in providing a competitive advantage in the digital health industry. We will explore opportunities and challenges for protecting digital health technologies during the program, including patent eligibility challenges and the use of trade secrets.
ABOUT SOODY TRONSON
Soody Tronson is Founding Managing Counsel at STLG Law Firm, counseling domestic and international clients in IP and technology transactions in a wide range of technologies. In 2016 she formed, Presque, a company developing a line of medical devices for mothers and infants.
Soody has over 25 years of operational experience in technology, business, management, and law in start-up and fortune 100 companies, including Schering Plough Pharmaceuticals, Hewlett-Packard Co., Avantec Vascular, and the law firms of HellerEhrman and Townsend and Townsend.
Soody serves in board and leadership capacities with several organizations including the Association of Women in Science STEM to Market national accelerator; Licensing Executives Society USA/Canada, California Lawyers Association, and the Palo Alto Area Bar Association. Soody is a Commissioner with the city of Menlo Park; and an active hands-on volunteer with several civic organizations including Defy Ventures, an entrepreneurship training program for currently and formerly incarcerated. Soody has instructed courses in IP, licensing, and entrepreneurship at the University of California, Stanford University and European institutions. She is the co-author of the book “Women Securing the Future with TIPPSS for IoT: Trust, Identity, Privacy, Protection, Safety, Security for the Internet of Things.”
Hosted by: Garry Gold, MD
Sponsored by the PHIND Center and the Department of Radiology
![PHIND Seminar - Andrew Lipchik, Ph.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Unknown-225x300.jpeg)
PHIND Seminar Series: Serum Modulation of Mitochondrial Function as a Scalable Sensor of Insulin Resistance
Andrew Lipchik, Ph.D.
Postdoctoral Fellow – Michael Snyder Lab
Stanford University
11:00am – 12:00pm Seminar & Discussion
12:00pm – 12:15pm Reception & Light Refreshments
RSVP: https://stanford.zoom.us/webinar/register/7716009863360/WN_dbeuo7csS8q_AhR88XET0g
Location: Zoom
Webinar URL: . https://stanford.zoom.us/s/96358568342
Webinar ID: 963 5856 8342
Dial: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Password: 767148
ABSTRACT
The global epidemic of obesity is associated with the dramatic increase in the prevalence of type 2 diabetes mellitus (T2D) with an estimated 400 million people worldwide will have T2D by 2030. T2D is proceeded by insulin resistance (IR) for up to decades prior to onset of T2D. Current estimates suggest approximately one in three individuals are sufficiently insulin resistant to be at risk for IR complications including T2D, coronary heart disease and nonalcoholic fatty liver disease. IR often goes undiagnosed due to the complex, invasive and laborious nature of clamp assays preventing their universal application in the clinic. Surrogate measurements using fasting plasma glucose and insulin levels can estimate IR but are imprecise. There is a need for the identification of new biomarkers and assays for the detection and monitoring of IR. Here, we demonstrate the utility of cellular mitochondrial respiration in response to individuals’ serum as a sensor for personalized monitoring of insulin sensitivity. The modulation of insulin-dependent mitochondrial function by patient serum was highly correlated with insulin sensitivity as determined by the gold-standard modified insulin suppression test (IST). We further applied this methodology to monitor insulin sensitivity over time in response to illness as well as treatment with the insulin sensitizing medication, pioglitazone. Our results demonstrate the development and application of a novel surrogate measurement for the determination and monitoring of insulin sensitivity. This assay offers the advantages of minimal invasiveness and complexity compared to IST as well as superior correlation with IST compared to existing surrogate measurements.
ABOUT ANDREW LIPCHIK
Andrew Lipchik majored in Chemistry at Xavier University where he preformed research on the development of oxygen activation Ni(II) complexes with Dr. Craig Davis and Dr. Michael Baldwin at the University of Cincinnati. He went on to obtain his PhD from Purdue University under mentorship of Dr. Laurie Parker. His thesis work focused on identifying determinants of kinase substrate specificity. This understanding was applied to the development of novel kinase-specific peptide biosensors to monitor intracellular kinase activity. Following his graduate work, he joined the laboratory of Michael Snyder at Stanford University where he has focused on understanding the impact of the immune system on insulin resistance and glucose metabolism.
Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology
ZOOM LINK HERE
“High Resolution Breast Diffusion Weighted Imaging”
Jessica McKay, PhD
ABSTRACT: Diffusion-weighted imaging (DWI) is a quantitative MRI method that measures the apparent diffusion coefficient (ADC) of water molecules, which reflects cell density and serves as an indication of malignancy. Unfortunately, however, the clinical value of DWI is severely limited by the undesirable features in images that common clinical methods produce, including large geometric distortions, ghosting and chemical shift artifacts, and insufficient spatial resolution. Thus, in order to exploit information encoded in diffusion characteristics and fully assess the clinical value of ADC measurements, it is first imperative to achieve technical advancements of DWI.
In this talk, I will largely focus on the background of breast DWI, providing the clinical motivation for this work and explaining the current standard in breast DWI and alternatives proposed throughout the literature. I will also present my PhD dissertation work in which a novel strategy for high resolution breast DWI was developed. The purpose of this work is to improve DWI methods for breast imaging at 3 Tesla to robustly provide diffusion-weighted images and ADC maps with anatomical quality and resolution. This project has two major parts: Nyquist ghost correction and the use of simultaneous multislice imaging (SMS) to achieve high resolution. Exploratory work was completed to characterize the Nyquist ghost in breast DWI, showing that, although the ghost is mostly linear, the three-line navigator is unreliable, especially in the presence of fat. A novel referenceless ghost correction, Ghost/Object minimization was developed that reduced the ghost in standard SE-EPI and advanced SMS. An advanced SMS method with axial reformatting (AR) is presented for high resolution breast DWI. In a reader study, AR-SMS was preferred by three breast radiologists compared to the standard SE-EPI and readout-segmented-EPI.
“Machine-learning Approach to Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors: A Multicenter Study”
Michael Zhang, MD
ABSTRACT: Clinicoradiologic differentiation between benign and malignant peripheral nerve sheath tumors (PNSTs) is a diagnostic challenge with important management implications. We sought to develop a radiomics classifier based on 900 features extracted from gadolinium-enhanced, T1-weighted MRI, using the Quantitative Imaging Feature Pipeline and the PyRadiomics package. Additional patient-specific clinical variables were recorded. A radiomic signature was derived from least absolute shrinkage and selection operator, followed by gradient boost machine learning. A training and test set were selected randomly in a 70:30 ratio. We further evaluated the performance of radiomics-based classifier models against human readers of varying medical-training backgrounds. Following image pre-processing, 95 malignant and 171 benign PNSTs were available. The final classifier included 21 features and achieved a sensitivity 0.676, specificity 0.882, and area under the curve (AUC) 0.845. Collectively, human readers achieved sensitivity 0.684, specificity 0.742, and AUC 0.704. We concluded that radiomics using routine gadolinium enhanced, T1-weighted MRI sequences and clinical features can aid in the evaluation of PNSTs, particularly by increasing specificity for diagnosing malignancy. Further improvement may be achieved with incorporation of additional imaging sequences.
![PHIND Seminar - Ami Bhatt, M.D., Ph.D. & Gavin Sherlock, Ph.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/SpeakerMashUp-01-300x150.png)
PHIND Seminar Series: Identifying Microbiome Markers of Progression of Alzheimer’s Disease
Ami Bhatt, M.D., Ph.D.
Assistant Professor of Medicine (Hematology) and of Genetics
Stanford University
Gavin Sherlock, Ph.D.
Associate Professor of Genetics
Stanford University
11:00am – 12:00pm Seminar & Discussion
RSVP: https://stanford.zoom.us/webinar/register/8016040837299/WN_iBOM7R4XQjOPSb20rkUxbw
Location: Zoom Webinar
Webinar URL: https://stanford.zoom.us/s/99730716280
Webinar ID: 997 3071 6280
Dial: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Password: 767148
ABOUT AMI BHATT
In perpetual awe of how ‘simple’ microbial organisms can perturb complex, multicellular eukaryotic organisms, Ami Bhatt has chosen to dedicate her research program to inspecting, characterizing and dissecting the microbe-human interface. Nowhere is the interaction between hosts and microbes more potentially impactful than in immunocompromised hosts and global settings where infectious and environmental exposures result in drastic and sometimes fatal health consequences.
Ami’s group identifies problems and questions that arise in the course of routine clinical care. Often in collaboration with investigators at Stanford and beyond, the group applies modern genetic, molecular and computational techniques to seek answers to these questions, better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease phenotypes.
GAVIN SHERLOCK’S RESEARCH INTERESTS
Adaptive Evolution and the Fitness Landscape: When yeast are evolved under various selective pressures in a chemostat, mutations that arise and provide an adaptive advantage will expand within the population. We have pioneered the use of high throughput sequencing to determine the identity of such mutations, as well as to understand the dynamics of the mutations within the populations, and the interactions between the mutations (such as epistasis). Further, we have developed a DNA barcode based lineage tracking system to determine the distribution of fitness effects (DFE) for newly arising beneficial mutations. We have also characterized what we call the genotype-fitness map for beneficial mutations, and have investigated why beneficial mutations provide a positive fitness effect. We are also interested in how beneficial mutations trade-off for different traits, and how those trade-offs constrain adaptive evolution.
Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology
![PHIND Seminar - Ahmed Metwally, Ph.D. & Pierre-Alexandre Fournier, M.S. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/cc595326-0d44-4f85-80d0-8d205ac3ed01-300x300.jpg)
PHIND Seminar Series: Topics Below
Ahmed Metwally, PhD
“Pre-symptomatic detection of COVID-19 via wearables biosensors”
Postdoctoral Scholar – Michael Snyder, PhD Lab
Department of Genetics
Stanford University
Pierre-Alexandre Fournier, MS
“Continuous remote cardiorespiratory and health monitoring using the Hexoskin biometric shirt”
Co-founder and CEO
Hexoskin
Location: Zoom Webinar
Webinar URL: https://stanford.zoom.us/s/98925964231
Dial: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 989 2596 4231
Passcode: 298382
11:00am – 12:00pm Seminar & Discussion
RSVP: https://stanford.zoom.us/webinar/register/WN_bruT-pvvQUePuBLqm2SLkQ
Ahmed Metwally Abstract
Wearable devices digitally measuring vital signs have been used for monitoring health and illness onset and have a high potential for real-time monitoring and disease detection. As such, they are potentially useful during public health crises, such as the current COVID-19 global pandemic. In my talk, I’ll discuss how wearables biosensors can be used as a tool to early detect COVID19 onset using physiological and activity data. By using retrospective smartwatch data, we showed that 63% of the COVID-19 cases could be detected before symptom onset in real-time via the occurrence of extreme elevations in resting heart rate relative to the individual baseline. Our findings suggest that consumer wearables may be used for the large-scale real-time detection of respiratory infections, often pre-symptomatically, and provide an approach for managing epidemics using digital tracking and health monitoring.
About Ahmed Metwally
Ahmed Metwally is a postdoctoral scholar in the Snyder lab at Stanford University. Ahmed received his Ph.D. in Bioinformatics/Bioengineering and MS in Computer Science (focused on Deep Learning), both from the University of Illinois at Chicago (UIC) in 2018. He currently works on developing novel machine learning methods for longitudinal multimodal biomedical data fusion (omics and wearable biosensors data) to early detect cardiometabolic diseases and personalize their treatments. Ahmed has received numerous awards, such as NIH Predoctoral Translational Scientist fellowship, ISMB’20 best talk award, Stanford COVID-19 RISE Grant, second-place award at Stanford Health++ Hackathon, and many travel awards NSF, IEEE, ISCB, and UIUC for various educational and scholarly activities.
Pierre-Alexandre Fournier Abstract
The Hexoskin Connected Health platform will be discussed as an example of a biometric shirt validated for use in telehealth and clinical research. Hexoskin has the only clinically validated biometric garment which provides continuous monitoring of numerous and unique physiological parameters. Hexoskin is an enabling technology for telehealth use cases, such as remote patient monitoring, rehab, and detect the onset of illness. Hexoskin offers a unique set of high-resolution biometric data that can continuously monitor activity, sleep, cardiac and respiratory data. Projects in fields such as cardiology, respiratory, behavioral and physiological psychology, biofeedback research, sleep research, and health will be described. The Hexoskin Connected Health Platform provides researchers with accessible solutions such as the Hexoskin Dashboards, Open API, and Apps to manage, visualize, annotate, analyze, and export raw & processed health data. Data extraction tools allow access to the raw data with time series for machine learning and artificial intelligence projects.
About Pierre-Alexandre Fournier
Pierre-Alexandre Fournier is co-founder and CEO of Hexoskin, a Montreal-based company focused on clinical-grade wearable sensors and AI software for health and clinical research. Hexoskin was founded in 2006 and in 2013 released the first iPhone compatible smart clothing for health monitoring, winning several international awards. In 2018 Hexoskin launched a remote health monitoring system for astronauts on the International Space Station. Hexoskin recently reached the milestone of 100 scientific publications. Pierre-Alexandre earned his MASc and his BEng in Electrical Engineering from the Ecole Polytechnique de Montreal and became a lecturer there teaching machine learning. He completed the Harvard Business School HBX Core program with high honors. Pierre-Alexandre is also an advocate for transparency in healthcare, patient empowerment, and healthcare innovation through design.
Hosted by: Angela McIntyre, Executive Director, eWEAR Initiative
Sponsored by: PHIND Center, Department of Radiology, eWEAR Initiative
![MIPS Seminar - Carolyn Bertozzi, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Carolyn-Bertozzi-2017-Final-2-Credit-American-Chemical-Society-216x300.png)
MIPS Seminar Series: Translational Opportunities in Glycoscience
Carolyn Bertozzi, PhD
Director, ChEM-H
Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences
Professor, by courtesy, of Chemical and Systems Biology
Stanford University
Location: Zoom
Webinar URL: . https://stanford.zoom.us/j/94010708043
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 940 1070 8043
Passcode: 659236
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
Cell surface glycans constitute a rich biomolecular dataset that drives both normal and pathological processes. Their “readers” are glycan-binding receptors that can engage in cell-cell interactions and cell signaling. Our research focuses on mechanistic studies of glycan/receptor biology and applications of this knowledge to new therapeutic strategies. Our recent efforts center on pathogenic glycans in the tumor microenvironment and new therapeutic modalities based on the concept of targeted degradation.
ABOUT
Carolyn Bertozzi is the Baker Family Director of Stanford ChEM-H and the Anne T. and Robert M. Bass Professor of Humanities and Sciences in the Department of Chemistry at Stanford University. She is also an Investigator of the Howard Hughes Medical Institute. Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology. She is an elected member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. She also has been awarded the Lemelson-MIT Prize, a MacArthur Foundation Fellowship, the Chemistry for the Future Solvay Prize, among many others.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![PHIND Seminar - Thalia Robakis, M.D., Ph.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Robakis-headshot-240x300.jpg)
PHIND Seminar Series: Maternal Trauma History, Attachment Style, and Depression Are Associated with Broad DNA Methylation Signatures in Infants
Thalia Robakis, M.D., Ph.D.
Associate Professor
Department of Psychiatry
Mount Sinai School of Medicine
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/95483174518
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 954 8317 4518
Passcode: 179384
11:00am – 12:00pm Seminar & Discussion
RSVP Here
ABSTRACT
Background: The early environment provides many cues to young organisms that guide their development as they mature. Maternal personality and behavior are an important aspect of the environment of the developing human infant. The molecular mechanisms by which these influences are exerted are not well understood. We attempted to identify whether maternal traits could be associated with alterations in DNA methylation patterns in infants.
Methods: 32 women oversampled for history of depression were recruited in pregnancy and provided information on depressive symptoms, attachment style, and history of early life adversity. Buccal cell DNA was obtained from their infants at six months of age for a large-scale analysis of methylation patterns across 5×106 individual CpG dinucleotides, using clustering-based criteria for significance to control for multiple comparisons. Separately, associations between maternal depression, attachment style, and history of adversity and psychobehavioral outcomes in preschool-age children were examined.
Results: Tens of thousands of individual infant CpGs were alternatively methylated in association with each of the three studied maternal traits. Genes implicated in cell-cell communication, developmental patterning, growth, immune function/inflammatory response, and neurotransmission were identified. The result sets were highly coextensive among the three maternal traits, but areas of divergence exhibited intriguing parallels with behavioral outcomes.
Conclusions: Maternal personality traits are an important aspect of the infant environment that shapes offspring development in many ways. Infant genes that are epigenetically modified in reponse to maternal traits are potential candidate mediators for these effects. We have identified a large number of such genes and demonstrated parallels to clinically measurable outcomes in children.
ABOUT
Dr. Robakis is a psychiatrist with clinical and research interests in perinatal mood disorders and in the contribution of early life experiences to adult mental health and illness. She completed her M.D. as well as a Ph.D. in developmental neurobiology at Columbia University’s Medical Scientist Training Program, residency training in psychiatry at Stanford University School of Medicine, and a research fellowship in perinatal mood disorders also at Stanford. She remained on the clinical faculty at Stanford until 2019, when she accepted a position at the Icahn School of Medicine at Mount Sinai, where she is currently Associate Clinical Professor of Psychiatry and Assistant Director of the Women’s Mental Health Program.
Dr. Robakis’ research interests include the effects of early life stress and disordered attachment on risk for psychiatric illness in the perinatal period, on alterations in metabolism and cognition, and on psychobehavioral development in offspring. She is particularly interested in using epigenetic marks to help identify the biological pathways through which early life experiences exert their effects on outcomes in adulthood and intergenerationally.
Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology
![MIPS Seminar - Joseph M. DeSimone, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Joe-Crop-5-240x300.jpg)
MIPS Seminar Series: “Convergent, translational research to improve human health”
Joseph M. DeSimone, PhD
Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering
Departments of Radiology and Chemical Engineering
Graduate School of Business (by Courtesy)
Stanford University
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/98460805010
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 984 6080 5010
Passcode: 809226
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
In many ways, manufacturing processes define what’s possible in society. Central to our interests in the DeSimone laboratory are opportunities to make things using cutting-edge fabrication technologies that can improve human health. This lecture will describe advances in nano- / micro-fabrication and 3D printing technologies that we have made and employed toward this end. Using novel perfluoropolyether materials synthesized in our lab in 2004, we invented the Particle Replication in Non-wetting Templates (PRINT) technology, a high-resolution imprint lithography-based process to fabricate nano- and micro-particles with precise and independent control over particle parameters (e.g. size, shape, modulus, composition, charge, surface chemistry). PRINT brought the precision and uniformity associated with computer industry manufacturing technologies to medicine, resulting in the launch of Liquidia Technologies (NASDAQ: LQDA) and opening new research paths, including to elucidate the influence of specific particle parameters in biological systems (Proc. Natl. Acad. Sci. USA 2008), and to reveal insights to inform the design of vaccines (J. Control. Release 2018), targeted therapeutics (Nano Letters 2015), and even synthetic blood (PNAS 2011). In 2015, we reported the invention of the Continuous Liquid Interface Production (CLIP) 3D printing technology (Science 2015), which overcame major fundamental limitations in polymer 3D printing—slowness, a very limited range of materials, and an inability to create parts with the mechanical and thermal properties needed for widespread, durable utility. By rethinking the physics and chemistry of 3D printing, we created CLIP to eliminate layer-by-layer fabrication altogether. A rapid, continuous process, CLIP generates production-grade parts and is now transforming how products are manufactured in industries including automotive, footwear, and medicine. For example, to help address shortages, CLIP recently enabled a new nasopharyngeal swab for COVID-19 diagnostic testing to go from concept to market in just 20 days, followed by a 400-patient clinical trial at Stanford. Academic laboratories are also using CLIP to pursue new medical device possibilities, including geometrically complex IVRs to optimize drug delivery and implantable chemotherapy absorbers to limit toxic side effects. Vast opportunities exist to use CLIP to pursue next-generation medical devices and prostheses. Moreover, CLIP can improve current approaches; for example, the fabrication of an iontophoretic device we invented several years ago (Sci. Transl. Med. 2015) to drive chemotherapeutics directly into hard-to-reach solid tumors is now being optimized for clinical trials with CLIP. New design opportunities also exist in early detection, for example to improve specimen collection, device performance (e.g. microfluidics, cell sorting, supporting growth and studies with human organoids), and imaging (e.g. PET detectors, ultrasound transducers). Here at Stanford, we are pursuing new 3D printing advances, including software treatment planning for digital therapeutic devices in pediatric medicine, as well as the design of a high-resolution printer capable of single-digit micron resolution to advance microneedle designs as a potent delivery platform for vaccines. The impact of our work on human health ultimately relies on our ability to enable a convergent research program to take shape that allows for new connections to be made among traditionally disparate disciplines and concepts, and to ensure that we maintain a consistent focus on the translational potential of our discoveries and advances.
ABOUT
Joseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with a courtesy appointment in Stanford’s Graduate School of Business. Previously, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 – 2019) of the additive manufacturing company, Carbon.
DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing, also co-founding several companies based on his research. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM. In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He is also one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology